MIDAZOLAM
Generic: MIDAZOLAM HYDROCHLORIDE
HospiraManufacturer
INTRAMUSCULAR, INTRAVENOUSRoute
MIDAZOLAM HYDROCHLORIDEActive Substance
2000-06-20Original Approval
MIDAZOLAM is FDA application ANDA075293, sponsored by HOSPIRA. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2012-09-27
MIDAZOLAM HYDROCHLORIDE INJECTION, 5 mg/1 mL, C-IV, For IM or IV Use, 2 mL Vials, Rx only. APP Pharmaceuticals, LLC. ScLack of Assurance of Sterility: Glass vials may have finish fractures and glass particles.
Class I2017-10-27
Midazolam Injection, USP, Preservative Free, 2 mg / 2 mL (1 mg / mL), 24 X 2mL Prefilled single-use syringes per carton,Labeling: Label MIX-UP. Blister Packages, Labeled as Midazolam injection, USP, 2 mg / 2 ml, Contain
Class II2016-12-16
MIDAZOLAM INJECTION, USP, *25 mg/5 mL, (5 mg/ mL), 5 mL vials, 10 Vials per carton, Rx only, APP Pharmaceuticals, LLC ScFailed Impurities/Degradation Specifications
Top Reported Reactions
1
DRUG INEFFECTIVE
3,477 reports
2
OFF LABEL USE
2,614 reports
3
HYPOTENSION
1,627 reports
4
DRUG INTERACTION
1,261 reports
5
SEIZURE
1,229 reports
6
PYREXIA
978 reports
7
TOXICITY TO VARIOUS AGENTS
954 reports
8
CARDIAC ARREST
950 reports
9
ACUTE KIDNEY INJURY
946 reports
10
DEATH
742 reports